Ex) Article Title, Author, Keywords
Ex) Article Title, Author, Keywords
Pharmacoepidemiology and Risk Management 2023; 15(2): 117-127
Published online September 30, 2023 https://doi.org/10.56142/perm.23.0019
Copyright © Korean Society for Pharmacoepidemiology and Risk Management.
Su Yeon Lee1,2, Hyun Jee Kim1,2, Jiung Jeong3*, Hye-Ryun Kang1,2,3*
이수연1,2, 김현지1,2, 정지웅3*, 강혜련1,2,3*
Correspondence to:Hye-Ryun Kang
Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro Jongno-gu, Seoul 03080, Korea
Tel: +82-2-2072-3291
Fax: +82-2-742-3291
E-mail: helenmed@snu.ac.kr
Jiung Jeong
Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro Jongno-gu, Seoul 03080, Korea
Tel: +82-2-2072-3291
Fax: +82-2-742-3291
E-mail: skjung1371@gmail.com
*These authors contributed equally.
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
All antineoplastic agents can potentially cause hypersensitivity reactions. Hypersensitivity reactions to antineoplastic agents may not provide patients with optimal treatment and may affect future survival. Hypersensitivity reactions to antineoplastic agents are classified by time of onset of symptoms. If it occurs within 1–6 hours, it is classified as an immediate hypersensitivity reaction, and after 1–6 hours as a delayed hypersensitivity reaction. Mechanisms that cause hypersensitivity reactions to antineoplastic agents differ from drug to drug, and management strategies that match those mechanisms must be used. Management of hypersensitivity reactions to antineoplastic agents includes culprit antineoplastic agent withdrawal, administration after premedication, and desensitization of culprit antineoplastic agent. A better understanding of these management strategies can provide the best antineoplastic agent therapy for patients. In addition to this, it can prevent events leading to death and developing severe reactions. Although there have been many reports on the hypersensitivity reactions of antineoplastic agents, there are very few literatures detailing the hypersensitivity characteristics of individual antineoplastic agents. The purpose of this review is to improve the understanding of the hypersensitivity reactions of individual antineoplastic agents and to reduce the incidence of hypersensitivity reactions by proposing a premedication method.
KeywordsAntineoplastic agents, Monoclonal antibodies, Hypersensitivity, Premedication, Desensitization
